English 
Spanish 
Arabic 
Chinese 
French 
DBL™ buttock contouring · Suitability and risk assessment
Suitability for DBL™ buttock contouring is not determined by a preferred body shape or by choosing a filler volume online. At Dr Ducu Clinics, we assess what creates the existing contour, which tissue layer could be modified, whether previous procedures have changed the anatomy and whether the medical and procedural risks are acceptable. A consultation may lead to treatment, a staged plan, further investigation, another option or a decision not to proceed.
The essential idea
Wanting a contour change is not the same as having a safe injectable target. Buttock appearance reflects the pelvis, gluteal muscles, fat distribution, skin envelope, scars and movement. The region also contains major blood vessels and nerves, while previous filler, fat transfer or implants may alter normal tissue planes. DBL™ is considered only when the proposed change is anatomically plausible, the product and tissue history are sufficiently clear, and the risks can be discussed and managed responsibly.
What suitability means for DBL™
DBL™ / Ducu Butt Lift is our doctor-led buttock contouring technique using hyaluronic acid-based dermal filler placed with a cannula according to an individual plan. It may be considered for selected volume, projection, symmetry, hip contour, dimpling or post-procedural irregularity concerns. It is not suitable for everyone, and the word “non-surgical” must not be mistaken for low risk.
In England, expert and regulatory guidance treats large-volume filler augmentation of the buttocks as a high-risk invasive procedure. The Joint Council for Cosmetic Practitioners states that buttock augmentation with dermal filler should be regarded as surgical in nature and performed in an appropriately regulated surgical setting by suitably qualified medical practitioners with relevant competence.
For us, suitability means that four questions have acceptable answers: is there a defined and reachable anatomical target; is the tissue history sufficiently known; is the person medically suitable for the proposed intervention; and is the expected change proportionate to the risks, limitations and recovery? Being generally healthy addresses only part of that decision.
Anatomy that shapes the decision
Labels such as A-shaped, round, V-shaped or square can describe an outline, but they do not provide a medical treatment plan. Two people with a similar external silhouette may have different skeletal proportions, muscle mass, subcutaneous thickness, skin quality, scar patterns and vascular anatomy.
Framework
Pelvis and proportions
Pelvic width, the greater trochanters, waist-to-hip relationship and leg alignment influence contour but cannot be changed by filler.
Dynamic volume
Muscle and movement
The gluteal muscles change shape with posture and contraction. A static photograph cannot show every functional difference.
Treatment envelope
Fat and skin
Subcutaneous thickness, laxity, cellulite, scars and the capacity of the tissues to accept added volume affect what may be reasonable.
Structures at risk
Vessels and nerves
Major gluteal vessels and the sciatic nerve make depth, location and technique clinically important; no anatomical map removes risk completely.
We examine the buttocks together with the flanks, hips, sacral region and upper thighs because a contour transition may matter more than a single depression. We also assess the area standing, at rest and where useful during movement. Natural side-to-side differences are documented rather than promised away.
Added product cannot narrow the pelvis, strengthen muscle, remove loose skin or guarantee a particular waist-to-hip ratio. When the requested change depends mainly on one of those factors, filler may be ineffective or disproportionate.
Similar-looking concerns can require different interpretations
A visible dip or flat area does not identify its own cause. The table shows why the same request can lead to different decisions.
| Concern being assessed | Possible contributors | Planning implication |
|---|---|---|
| Lateral hip depression | Pelvic and femoral anatomy, muscle insertions and local fat distribution. | Selected softening may be considered; complete removal or perfect symmetry cannot be promised. |
| Limited projection | Skeletal proportions, gluteal muscle, fat volume and posture. | The desired increase must fit tissue capacity and an acceptable product volume; dramatic enlargement may be unsuitable. |
| Cellulite or dimpling | Fibrous septa, skin quality, fat lobules and movement. | Some selected depressions may be considered, but filler does not treat every cellulite mechanism. |
| Apparent asymmetry | Pelvic rotation, leg-length difference, muscle, fat, scoliosis, scars or prior treatment. | Volume-related differences may be softened, while structural or functional asymmetry may remain. |
| Post-liposuction irregularity | Uneven fat thickness, fibrosis, tethering, skin laxity or unresolved swelling. | The cause must be mapped; adding filler is not an automatic repair and may make some patterns harder to manage. |
| Loose or hanging skin | Skin-envelope excess after pregnancy, ageing or substantial weight change. | Filler adds volume but does not remove skin; it may increase heaviness without correcting the main issue. |
The correct target should be stated in anatomical terms. “More curves” is a preference, not a treatment map. During consultation, we translate the preference into specific zones, define what cannot change and consider whether the volume needed remains proportionate.
Medical history and medicines are part of the anatomy decision
A risk assessment is not a formality completed after the contour plan. Health conditions and medicines may affect bleeding, infection, inflammation, healing, thrombosis, local anaesthesia and the ability to recognise or manage a complication.
| History area | Examples to disclose | Why it matters |
|---|---|---|
| Bleeding and clotting | A bleeding or clotting disorder, previous thrombosis, easy bruising and anticoagulant or antiplatelet medicines. | May alter bleeding, haematoma or thrombotic risk and require advice from the relevant prescribing clinician. |
| Infection and immunity | Active skin infection, recurrent abscesses, recent systemic infection, immune suppression or inflammatory illness. | May increase infection or inflammatory risk and can make elective injection inappropriate at that time. |
| Healing and circulation | Diabetes, previous poor wound healing, significant vascular disease and nicotine exposure. | Can affect tissue recovery and how complications are assessed or managed. |
| Allergy and reactions | Known hypersensitivity to hyaluronic acid, product components, local anaesthetics, dressings or previous injectable reactions. | May contraindicate a product or require another plan; prior tolerance does not guarantee a future reaction will not occur. |
| Medicines and supplements | Prescribed medicines, over-the-counter products, hormones, weight-management treatment and herbal or gym supplements. | Interactions and effects on bleeding, immunity or recovery cannot be assessed if the list is incomplete. |
| Pregnancy and breastfeeding | Current pregnancy, breastfeeding or recent major physiological change. | Our procedure page lists pregnancy and breastfeeding among situations in which product injection is contraindicated. |
Do not stop prescribed medicine to become “suitable”
Tell us about every medicine and supplement. Do not stop or change an anticoagulant, antiplatelet medicine or any other prescribed treatment unless the prescribing clinician and treating doctor advise you to do so. An elective cosmetic plan must adapt to safe medical care—not the reverse.
Previous filler, fat transfer, liposuction or implants can change the tissue map
A history of buttock treatment must be disclosed even if it took place abroad, many years ago or under another product name. Unknown or permanent material can migrate, become infected, form granulomas or cross tissue planes. Injecting into tissue that already contains an unidentified product can make diagnosis and future management more difficult.
Previous filler
Product and plane matter
Bring the product name, quantity, dates, injection sites and records. “Dissolvable” should not be assumed without verification.
Fat transfer or liposuction
Scars and fibrosis matter
Uneven fat thickness, tethering, altered sensation and scar tissue may change cannula movement, filler distribution and risk.
Buttock implants
The device must be understood
Implant position, symptoms, operative details and any suspected complication require assessment before an injectable plan is considered.
Previous complication
Cause comes before correction
Pain, infection, drainage, migration, collections, nodules or tissue damage may require imaging, records, referral or treatment rather than more filler.
Our official procedure information lists a history of complications after permanent gluteal products—such as silicone, acrylic polymers or dextran—among contraindications to product injection. The exact substance may be unclear from memory or an old receipt, so uncertainty itself can be clinically important.
Where appropriate, we may use ultrasound to assess anatomy, locate vessels, review previous filler or identify variation. Published imaging research supports ultrasound as a useful method for characterising gluteal filler and mapping its distribution. It improves information; it does not certify that a further injection is safe or replace clinical judgement.
How we assess risk before recommending a plan
Risk is created by the interaction of the person, anatomy, product, technique, treatment volume and care system. It cannot be reduced to a consent form or an ultrasound image.
Stage 01
Define the target
We identify the exact contour feature, its likely anatomical cause and what would remain unchanged.
Stage 02
Map tissue history
We examine scars and tissue quality and review filler, surgery, implant and complication records where available.
Stage 03
Assess medical risk
We consider health, medicines, allergies, bleeding, infection, healing, pregnancy and the ability to follow aftercare.
Stage 04
Test proportionality
We compare the likely benefit with product volume, procedural risk, uncertainty, recovery and alternative options.
A larger requested change does not simply justify more filler. Tissue capacity, local pressure, product behaviour, existing material and the number of access points may affect planning. Where treatment remains appropriate, more than one session may be considered rather than pursuing the complete change at one appointment. Staging can support reassessment, but it does not make a high-risk procedure risk-free.
We also assess whether the decision is voluntary and informed. GMC guidance requires doctors to discuss benefits, material risks, reasonable alternatives and the option of no treatment, while allowing time for reflection and considering psychological needs or vulnerabilities.
When we may proceed, pause or decline
The outcome of assessment is not automatically an injection appointment. The appropriate decision depends on the combined findings.
| Possible outcome | When it may arise | What follows |
|---|---|---|
| Consider a DBL™ plan | There is a defined soft-tissue target, adequate information, acceptable medical risk and a proportionate goal. | We discuss zones, product, estimated volume, limitations, material risks, aftercare and review. |
| Modify or stage the plan | The target may be appropriate, but the requested scale, tissue capacity or uncertainty calls for a more limited approach. | A smaller initial plan or later reassessment may be discussed without promising further treatment. |
| Pause for information or recovery | Records are missing, previous material is uncertain, tissue is still healing or a health issue requires clarification. | We may request records, imaging, medical input or additional healing time before reconsideration. |
| Choose another pathway | The main concern is skin excess, an implant complication, infection, substantial surgical contouring or another non-filler problem. | Another qualified service, specialist assessment or no treatment may be more appropriate. |
| Decline treatment | A contraindication, unacceptable uncertainty, disproportionate request or risk that cannot be adequately mitigated is identified. | We explain the reason and do not proceed merely because treatment has been requested or paid for elsewhere. |
Evidence must be interpreted in the context of a high-risk procedure
Research on hyaluronic acid gluteal augmentation remains limited compared with many established procedures. A 2023 systematic review included ten reports and 168 patients. It found reported contour and satisfaction benefits, but also inflammation, effusion, migration, irregularity and rare major complications, including a death. The authors called for better controlled research.
More recent retrospective series have reported favourable outcomes in selected cohorts, but observational results do not remove the risk of rare serious events. Some studies also include manufacturer involvement, limited sample sizes or relatively short follow-up. Their findings cannot determine an individual’s safety or establish that every product, volume, technique and provider is equivalent.
The long-term behaviour of large-volume body filler is not fully understood. Product choice, placement, previous material, infection control, practitioner competence, emergency arrangements and continuity of care remain important parts of consent—not background details.
Potential complications and warning signs
Expected short-term effects can include swelling, bruising, tenderness, redness, entry marks, localised numbness and temporary asymmetry. More serious or prolonged complications may include infection, abscess, bleeding, persistent swelling, filler migration, lumpiness, granuloma, inflammatory or allergic reaction, contour irregularity, scarring, delayed healing, tissue damage or necrosis, vascular compromise, embolic events, an unsatisfactory result and the need for filler removal, hospital care or surgery.
Contact us promptly if recovery is unexpected or worsening
After treatment with us, contact our clinical team promptly for severe or increasing pain, rapidly worsening or one-sided swelling, spreading redness, fever, pus or drainage, blistering, pale or darkening skin, increasing heat, a new or enlarging lump, wound breakdown, marked numbness or weakness, or any symptom identified in your individual aftercare as urgent.
Call 999 for sudden breathlessness, chest pain, collapse, confusion, coughing blood, signs of stroke or a severe allergic reaction. These symptoms require emergency assessment rather than waiting for a routine review. NHS 111 can advise when urgent help is needed but the situation is not immediately life-threatening.
Hyaluronic acid may sometimes be treated with hyaluronidase, but “dissolvable” does not mean that every complication is easily reversible. Dissolution may be incomplete and cannot undo infection, vascular injury, tissue loss, scarring or every migrated deposit.
Questions to ask during consultation
- Which anatomical feature creates the contour concern I want assessed?
- What can filler change, and which skeletal, muscular, skin or postural features will remain?
- Does my tissue have the capacity for the requested change without using a disproportionate volume?
- How do my medicines, health conditions, nicotine exposure or healing history affect risk?
- How will previous filler, fat transfer, liposuction or implants be identified and assessed?
- Would ultrasound provide useful information in my case, and what can it not establish?
- What product and tissue plane are proposed, and why are they appropriate for this target?
- What complications can occur, and what emergency equipment, referral pathway and out-of-hours support are available?
- Why might treatment be staged, postponed or declined, and what alternatives include no treatment?
Frequently asked questions
Does a particular buttock shape determine suitability?
Can someone with very little body fat be considered?
Is loose buttock skin a good indication for filler?
Does cellulite make someone suitable for DBL™?
What if I do not know which filler was previously injected?
Can DBL™ be performed when buttock implants are present?
Does a previous buttock infection affect suitability?
Can I have treatment while taking blood-thinning medicine?
Do autoimmune or inflammatory conditions prevent DBL™?
Can DBL™ be performed during pregnancy or breastfeeding?
Why do smoking and vaping need to be disclosed?
Can training or building gluteal muscle replace filler?
Does splitting treatment into sessions remove the risk?
Why are expectations and psychological wellbeing assessed?
Why might we decline DBL™ after consultation?
Individual assessment
Assess anatomy, treatment history and risk before deciding
Our consultation examines the anatomical cause of the contour concern, health, medicines, previous procedures, tissue capacity, realistic limitations and potential complications. Booking an assessment does not commit you or us to treatment.
Medical and regulatory sources consulted
- Dr Ducu Clinics: Non-Surgical BBL / DBL™ in London
- JCCP: Buttock augmentation and other body contouring procedures—expert position
- Care Quality Commission: Choosing cosmetic surgery
- Effectiveness and Role of Using Hyaluronic Acid Injections for Gluteal Augmentation: systematic review
- Reviewing the Ultrasound Anatomy of the Gluteal Region and the Mapping of Fillers
- Nonsurgical Gluteal Volume Correction with Hyaluronic Acid: retrospective safety and efficacy study
- Clinical Evaluation of Hyaluronic Acid Filler for Gluteal Augmentation: retrospective study
- Management of Large-Quantity Permanent Gluteal Copolyamide Fillers: review and algorithm
- GMC: Guidance for doctors who offer cosmetic interventions
- ASA/CAP: Guidance on marketing cosmetic interventions